Abstract: The present disclosure is directed to compositions and methods of treating arthritogenic alphavirus infection. Compositions include a fusion protein comprising an Fc region, a first Mxra8 region, and a second Mxra8 region, wherein the fusion protein reduces inflammation and infection by an arthritogenic alphavirus. Methods include administering the fusion protein to a mammalian or non-mammalian subject to reduce or inhibit alphavirus infection.

Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.

Abstract: Systems and methods are disclosed for prioritizing vehicle charging using energy from renewable/low carbon emission energy sources over non-renewable/high carbon emission energy sources. The proposed systems and methods allow users to identify when to charge their vehicles and/or when to provide energy from their vehicles to other structures based on a currently available energy source mixture and in a manner that minimizes the impact to the environment. In-vehicle connectivity may be utilized to obtain real-time grid information, and a charging schedule may then be created that intelligently prioritizes charging during times when an energy mixture percentage available from renewable/low carbon emission sources exceeds a predefine threshold or when a real-time emissions level is below a predefined threshold.

Abstract: This disclosure is generally directed to systems and methods related to providing assistance services to a disabled vehicle. In an example embodiment, a method executed by a first processor in a vehicle may involve detecting an event that places the vehicle in a disabled condition; transmitting information associated with the event to a second processor; and detecting an arrival of a assistance vehicle that is dispatched by the second processor based on an automated evaluation of the information associated with the event. The second processor, which can be, for example, a part of a server computer, may evaluate the information in order to identify an assistance vehicle having equipment for providing the assistance service. In an example scenario, the disabled vehicle and/or the assistance vehicle can be an autonomous vehicle.

Abstract: An automated syringe handling system that will safely, securely, and quickly assemble syringes or other medical devices under controlled/sterile conditions while maintaining the syringes in a stable orientation and eliminating unnecessary operator contact with the syringes and working area.

Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.

Abstract: A device may include a captive rigid support plate. A device may include an inflatable bladder including one or more inflatable bladder portions made of airtight material. A device may include a rigid external surface wherein, the rigid external surface includes an area proximal to the captive rigid support plate. A device may include a hose-receiving interface coupled to at least one of the inflatable bladder portions. A device may include an inflation hose coupled to the hose-receiving interface. A device may include an inflating component coupled to the inflation hose. A device may include an integrated bleed valve coupled to one or more of at least one of the inflatable bladder portions, the inflation hose, or the inflating component.

Abstract: Compositions and methods useful for vaccinating for or preventing a Coronavinus infection, antibody screening, and variant prediction are provided. The present disclosure also provides for compositions and methods useful for sera diagnostics, treatment screening, and methods of making the compositions described herein.

Abstract: Polypeptide inhibitors of SARS-COV-2 are disclosed comprising an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-17, 19-21, 23-34 and 100-101, and their use for treating and limiting development of SARS-COV-2 infection.

Abstract: Compositions and methods for treating a viral infection may comprise use of an adenoviral vector. An adenoviral vector of the present disclosure may comprise a non-human adenoviral genome with one or more gene locus functionally removed and a transgene. A method of treating a viral infection may comprise administering a composition comprising an adenoviral vector of the present disclosure, to a subject and reducing the infectivity or transmission of the virus. Intranasal administration provides enhance protection of the upper respiratory tract of a subject relative to intramuscular administration.

Abstract: Compositions and methods for treating a viral infection may comprise use of a viral recognition-site inhibiting agent composition. A viral recognition-site inhibiting agent composition of the present disclosure may substantially inhibit, reduce, or block virus bind to the LDLRAD3 host receptor and reduces the infectivity of a virus for a host cell. A method of treating a viral infection may comprise administering a composition comprising a viral recognition-site inhibiting agent of the present disclosure, to a subject and reducing the infectivity of the virus for a host cell of the subject. The compositions may be administered via intranasal or systemic administration to treat or prevent a viral infection, for example an alphavirus infection.

Abstract: The present invention relates to antibodies or antigen-binding fragments that are useful for treating coronavirus infections (e.g., COVID-19 caused by SARS-CoV-2). The present invention also relates to various pharmaceutical compositions and methods of treating coronavirus using the antibodies or antigen-binding fragments.

Abstract: A system for a vehicle includes a first closure panel of the vehicle operable between open and closed positions, a second closure panel of the vehicle operable between open and closed positions, at least one sensor that is coupled to the first closure panel and that detects precipitation, and a controller that prompts movement of the first closure panel from a first open position to a second open position based on the detected precipitation.

Abstract: A system for a vehicle comprises first and second closure panels of the vehicle that are operable between open and closed positions, and at least one sensor coupled to the first closure panel that detects an obstruction in a pivot path of the second closure panel. The first closure panel forms at least a portion of a rear gate assembly of the vehicle. A controller receives data from the at least one sensor and prompts a vehicle action based on the received data.

Abstract: A system for a vehicle includes a human-machine interface, a microphone that detects sound, a sound source device that emits sound, and a controller that prompts pairing of the sound source device and the microphone, such that the sound source device emits sound corresponding to the sound detected by the microphone. The controller prompts pairing of the sound source device and the microphone in response to at least one of (i) the vehicle entering a reverse mode, and (ii) receiving a user input entered into the human-machine interface via selection of an input option by a user, wherein the input option is made accessible for selection by the user in response to the vehicle entering the reverse mode.

Abstract: A system for a vehicle having a trailer coupled thereto includes a rear gate assembly of the vehicle having a first closure panel operable between an open position and a closed position. The system also includes at least one sensor coupled to the first closure panel. The system further includes a controller that prompts execution of a security measure in response to the at least one sensor detecting a person within a predetermined proximity of at least a portion of the trailer.

Abstract: An example computing device includes a printed circuit board comprising: a first layer including one or more ground signal paths; a second layer including one or more ground signal paths; a third layer disposed between the first layer and the second layer; a radar antenna portion comprising a first radar antenna and electrically connected to a distal connector of the printed circuit board; a radar clock signal line configured to convey a radar clock signal between the radar antenna portion and the distal connector; and a first ground guard trace electrically coupled to the one or more ground signal paths and positioned adjacent to a first side of the radar clock signal line and parallel to a length of the radar clock signal line.

Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.

Abstract: A system for providing access to a vehicle includes first and second closure panels of the vehicle that are operable between open and closed positions. The system also includes a sensing system of the vehicle that senses at least one characteristic of a user positioned in an exterior environment of the vehicle. The system further includes a controller that determines a load carrying condition of the user based on the at least one characteristic of the user sensed by the sensing system. The controller prompts movement of the first closure panel from the closed position to the open position based on a determination of a first load carrying condition of the user. The controller also prompts movement of the first and second closure panels from the closed positions to the open positions based on a determination of a second load carrying condition of the user.

Abstract: The present invention relates to antibodies or antigen-binding fragments that are useful for treating coronavirus infections (e.g., COVID-19 caused by SARS-CoV-2). The present invention also relates to various pharmaceutical compositions and methods of treating coronavirus using the antibodies or antigen-binding fragments.